Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
January 24, 2024 07:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
January 24, 2024 03:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
September 26, 2023 09:30 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or...